A Phase 3 interventional study of Lopinavir/ritonavir and Ritonavir in HIV Infections, sponsored by Abbott. Completed at 7 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2006-08-15.
Sponsored by Abbott · Phase 3, Interventional, and Treatment
The purpose of this study is to determine the safety and effectiveness of a high dose of ABT-378/ritonavir
4,259 studies on the registry are indexed under HIV Infections; 241 are open to participants now.
This study's enrollment of 36 is below the median of 83 across 3,252 interventional studies indexed under HIV Infections.
Browse HIV Infections studies →Abbott is the lead sponsor of 350 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion:
Virologic and immunologic activity evaluations include plasma HIV RNA, CD4 and CD8 cell counts
This study is completed, as verified in Aug 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Abbott